NUTRILIPID 20%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUTRILIPID 20% (NUTRILIPID 20%).
Nutrilipid 20% is an intravenous fat emulsion providing a source of calories and essential fatty acids. It is composed of soybean oil, egg yolk phospholipids, and glycerin. The triglycerides in the emulsion are hydrolyzed by lipoprotein lipase into free fatty acids and glycerol, which are then metabolized for energy production and incorporation into cell membranes.
| Metabolism | The fat emulsion is cleared from the bloodstream by the reticuloendothelial system. The triglycerides are hydrolyzed by lipoprotein lipase, and the resulting free fatty acids are metabolized primarily in the liver and peripheral tissues via beta-oxidation. |
| Excretion | NUTRILIPID 20% is a lipid emulsion; triglycerides are cleared from plasma via hydrolysis by lipoprotein lipase into free fatty acids and glycerol, which are then metabolized. Renal excretion of intact triglycerides is negligible (<1%); elimination is primarily metabolic, with less than 5% excreted unchanged in urine or feces. |
| Half-life | The terminal elimination half-life of triglycerides in NUTRILIPID 20% is approximately 30 minutes in healthy adults with normal lipid metabolism. In critically ill or lipemic patients, clearance is delayed, and half-life can exceed 6 hours, necessitating monitoring of serum triglycerides. |
| Protein binding | Intravenous lipids do not bind significantly to plasma proteins; free fatty acids released from triglyceride hydrolysis bind extensively to albumin (99% bound). The emulsion itself is not protein-bound; apolipoproteins (e.g., apoE, apoC-II) associate with lipid particles transiently for clearance. |
| Volume of Distribution | The volume of distribution (Vd) for lipid emulsions is not classically defined as they are confined to the vascular space initially; distribution into tissues occurs via lipoprotein metabolism. Apparent Vd for triglycerides is approximately 0.1-0.2 L/kg, reflecting limited extravascular distribution. Clinical correlation: Large Vd may indicate impaired clearance or hypertriglyceridemia. |
| Bioavailability | Intravenous: 100% bioavailability. Not administered via other routes; oral or intramuscular absorption is not applicable due to emulsion formulation and need for direct intravenous access. |
| Onset of Action | Intravenous infusion: Triglycerides are detectable in plasma immediately; equilibrium with endogenous lipid metabolism occurs within 30-60 minutes of continuous infusion. Maximal clearance rates are achieved after 2-4 hours of steady-state infusion. |
| Duration of Action | Intravenous infusion: Duration of effect depends on infusion rate and metabolic clearance. After cessation, plasma triglycerides return to baseline within 12-24 hours in patients with normal clearance. In patients with impaired clearance, elevation may persist for days. |
Intravenous infusion of 20% lipid emulsion: 1-2 g/kg/day (5-10 mL/kg/day) as part of parenteral nutrition; maximum infusion rate: 0.11 g/kg/h (0.55 mL/kg/h).
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based adjustments; use with caution in severe renal impairment due to fluid and electrolyte load. |
| Liver impairment | Contraindicated in severe hepatic insufficiency (Child-Pugh class C); reduce dose by 50% in moderate impairment (Child-Pugh class B) and monitor triglycerides. |
| Pediatric use | Neonates and infants: initial 0.5-1 g/kg/day (2.5-5 mL/kg/day), increase gradually to 2-3 g/kg/day (10-15 mL/kg/day) as tolerated; maximum infusion rate: 0.15 g/kg/h (0.75 mL/kg/h). |
| Geriatric use | Start at lower end of adult dose (1 g/kg/day) with slower infusion rate, monitor triglycerides and fluid status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUTRILIPID 20% (NUTRILIPID 20%).
| Breastfeeding | Lipid emulsions are components of human milk. M/P ratio not established. Use is considered compatible with breastfeeding. |
| Teratogenic Risk | No known teratogenic risk; lipid emulsions are essential nutrients. No specific fetal risks have been reported with use during any trimester. |
| Fetal Monitoring | Monitor serum triglycerides, liver function, coagulation parameters, platelet count, and signs of fat overload syndrome. In pregnancy, ensure adequate nutritional status. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to eggs, soybeans, peanuts, or any component of the emulsion.","Severe hyperlipidemia or lipoid nephrosis.","Pathological hyperlipemia.","Acute pancreatitis with hyperlipidemia."]
| Precautions | ["Monitor serum triglycerides and signs of fat overload syndrome (e.g., hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy) in patients receiving prolonged parenteral nutrition.","Use with caution in patients with severe hepatic disease, pulmonary disease, anemia, or coagulation disorders.","Do not administer if emulsion shows signs of separation or oiling out."] |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility. Essential fatty acids are required for reproductive function. |